VHL Ligand-Linker Conjugates 15 is primarily utilized in the field of targeted protein degradation, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). These conjugates play a crucial role in designing molecules that can selectively degrade disease-causing proteins by recruiting the ubiquitin-proteasome system. The VHL ligand component specifically binds to the von Hippel-Lindau E3 ubiquitin ligase, enabling the targeted degradation of proteins of interest. This approach is highly valuable in drug discovery, especially for treating conditions like cancer, neurodegenerative diseases, and other disorders driven by aberrant protein activity. Its application allows for the precise manipulation of cellular protein levels, offering a novel therapeutic strategy beyond traditional inhibition methods.